Since both FIR and TIF1γ/TRIM33 engage in Wnt-signaling pathway to suppress tumor progression [25–27], anti-FIRs antibodies could be helpful for the screening of dermatomyositis patients with malignancies as well as anti-TIF1γ/TRIM33 antibodies. Here, TRIM33 is linked to neoplasm.